A dramatic new understanding of how cancer rapidly evolves and becomes resistant to treatment has emerged from research at the University of California San Diego. Scientists have identified the enzyme N4BP2 as the key driver of a chaotic genetic process called chromothripsis, a phenomenon where chromosomes shatter and reassemble in a disordered fashion. This discovery, published in the journal Science, offers a potential new target for therapies aimed at slowing the progression of some of the most aggressive cancers.
Chromothripsis isn’t a gradual accumulation of genetic mutations. it’s a catastrophic event that can generate dozens or even hundreds of alterations in a single instance. This rapid burst of genomic change allows cancer cells to quickly adapt and overcome the effects of treatment. Researchers estimate that approximately one in four human cancers exhibit evidence of chromothripsis, with even higher rates observed in certain tumor types like osteosarcoma, an aggressive bone cancer, and many brain cancers. Understanding the mechanisms behind this process is crucial for developing more effective cancer treatments.
“This discovery finally reveals the molecular ‘spark’ that ignites one of the most aggressive forms of genome rearrangement in cancer,” said senior author Don Cleveland, Ph.D., professor of cellular and molecular medicine at UC San Diego School of Medicine and member of UC San Diego Moores Cancer Center. “By finding what breaks the chromosome in the first place, we now have a new and actionable point of intervention for slowing cancer evolution.” The identification of N4BP2 as the enzyme responsible for initiating chromothripsis represents a significant step forward in cancer research.
How Chromothripsis Unfolds: The Role of N4BP2
The process begins with errors during cell division, which can trap chromosomes inside tiny compartments called micronuclei. These micronuclei are fragile and prone to rupture, exposing the chromosome to enzymes that can cut DNA. Until now, the specific enzyme responsible for initiating this destructive chain reaction remained unknown. Researchers at UC San Diego systematically screened all known and predicted human nucleases – enzymes that cleave DNA – to pinpoint the culprit. Their investigation revealed that N4BP2 uniquely enters micronuclei and fragments the DNA within.
To confirm N4BP2’s role, the team conducted experiments where they removed the enzyme from brain cancer cells. The result was a dramatic reduction in chromosome shattering. Conversely, when N4BP2 was forced into the nucleus of otherwise healthy cells, intact chromosomes broke apart. “These experiments showed us that N4BP2 isn’t just correlated with chromothripsis. It is sufficient to cause it,” explained first author Ksenia Krupina, Ph.D., a postdoctoral fellow at UC San Diego. This finding provides the first direct molecular explanation for the beginning of catastrophic chromosome fragmentation.
The Connection to Aggressive Cancers and Extrachromosomal DNA
The researchers extended their investigation to analyze over 10,000 cancer genomes across various tumor types. They found a strong correlation between higher levels of N4BP2 activity and increased chromothripsis, as well as large-scale structural rearrangements within the genome. Notably, these tumors also exhibited elevated levels of extrachromosomal DNA (ecDNA), circular DNA fragments that often carry genes promoting cancer growth and resistance to therapy. UC San Diego Health Sciences provides images illustrating the process of N4BP2 infiltrating micronuclei and inducing DNA damage.
Tumors rich in ecDNA are notoriously difficult to treat, making them a major focus of cancer research. EcDNA has even been designated one of the Cancer Grand Challenges by the National Cancer Institute and Cancer Research UK. The new findings suggest that ecDNA isn’t a separate phenomenon, but rather a consequence of chromothripsis. By identifying N4BP2 as the initiating factor, the study provides a crucial entry point for understanding and potentially controlling these particularly unstable and dangerous forms of cancer genome instability.
Implications for Future Cancer Therapies
The discovery of N4BP2’s role in chromothripsis opens up new avenues for therapeutic intervention. “Understanding what triggers chromothripsis gives us a new way to think about stopping it,” Cleveland stated. “By targeting N4BP2 or the pathways it activates, we may be able to limit the genomic chaos that allows tumors to adapt, recur and become drug-resistant.” Researchers are now exploring strategies to inhibit N4BP2 activity, potentially preventing the catastrophic chromosome fragmentation that fuels cancer progression. Further research will be needed to determine the safety and efficacy of such approaches in clinical settings.
The study involved contributions from a large team of researchers at UC San Diego, as well as collaborators at the University of Cambridge and the Wellcome Trust Sanger Institute. The research was supported by grants from the National Institutes of Health, including R35GM122476, R01 ES030993-01A1, R01ES032547-01, U01CA290479-01, R01CA269919-01, R56 NS080939 and R01 CA258248.
Disclaimer: This article provides information about medical research and is not intended to provide medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The research team plans to continue investigating the mechanisms underlying chromothripsis and to explore potential therapeutic strategies targeting N4BP2. The next steps will involve preclinical studies to assess the effectiveness of N4BP2 inhibitors in various cancer models. We will continue to follow this research and provide updates as they become available.
Have thoughts on this story? Share your comments below.
Keep reading
